title: [Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal and appendiceal origin].
abstract: BACKGROUND
  We report our initial experience combining cytoreductive surgery (CRS) plus intraperitoneal chemotherapy with hyperthermia (HIPEC) in a selected group of patients presenting with disseminated peritoneal carcinomatosis (PC) of colorectaL or appendiceaL origin at a single tertiary referral institution.
  
  
  METHODS
  The study included patients who underwent CRS with HIPEC at the Sheba Medical Center between April 2009 and December 2011. The HIPEC technique was administered with the open Coliseum technique reaching a steady state of mitomycin-C delivery at 410 C for perfusion duration of 90 minutes.
  
  
  RESULTS
  AnaLysis included 45 patients (18 males) incorporating 42 cases of primary colorectal cancer (CRC) or appendiceal cancer and 3 cases of pseudomyxoma peritonei. Thirty-seven patients (82%) underwent CC-0 resections with a median overall hospital stay of 8 days (range 5-43). There was one perioperative death at 90 days. The perioperative complication rate was 31.1%. The median follow-up was 12 months (range 2-36) during which 13 patients died. Among the CRC and appendiceal cancer group the median overall survival was 20.2 months and the median progression free survival was 16.4 months (Kaplan-Meier analysis). During follow-up, 23 patients experienced disease progression.
  
  
  CONCLUSIONS
  The selective use of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis from colorectal or appendiceal origin is safe with acceptable morbidity and low mortality.
authors.forename: Yaniv
authors.initials: Y
authors.lastname: Berger
authors.forename: Andrew Paul
authors.initials: AP
authors.lastname: Zbar
authors.forename: Alexander
authors.initials: A
authors.lastname: Lebedyev
authors.forename: Yosef
authors.initials: Y
authors.lastname: Levi
authors.forename: Avinoam
authors.initials: A
authors.lastname: Nevler
authors.forename: Dan
authors.initials: D
authors.lastname: Aderka
authors.forename: Talia
authors.initials: T
authors.lastname: Golan
authors.forename: Ofer
authors.initials: O
authors.lastname: Purim
authors.forename: Baruch
authors.initials: B
authors.lastname: Brenner
authors.forename: Mahmud
authors.initials: M
authors.lastname: Natur
authors.forename: Mordechai
authors.initials: M
authors.lastname: Gutman
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D024221:Antineoplastic Protocols; D001063:Appendiceal Neoplasms / Q000401:mortality / Q000473:pathology; D002277:Carcinoma / Q000473:pathology / Q000556:secondary / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D053208:Kaplan-Meier Estimate; D008297:Male; D059146:Metastasectomy / Q000379:methods*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D010533:Peritoneal Lavage / Q000379:methods; D010534:Peritoneal Neoplasms / Q000473:pathology / Q000556:secondary / Q000628:therapy; D011183:Postoperative Complications / Q000145:classification / Q000209:etiology; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D016685:Mitomycin